Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 68-78

  Aharoni, Rina ^a   Kayhan, Basak ^a   Brenner, Ori ^a   Domev, Hagit ^a   Labunskay, Galya ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CLINICAL FEATURE; COLON INJURY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENTERITIS; FEMALE; GENE CONTROL; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATION; INTESTINAL BLEEDING; MICROSCOPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; PEPTIDES;

EID: 33745245732     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103192     Document Type: Article

References (30)

1. Aharoni R, Kayhan B, and Arnon R (2005) Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis 11:106-115.
2. Aharoni R, Kayhan B, Eilam R, Sela M, and Arnon R (2003) Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100:14157-14162.
3. Aharoni R, Teitelbaum D, Arnon R, and Sela M (2001) Copolymer 1 inhibits manifestation of graft rejection. Transplantation 27:598-605.
4. Aharoni R, Teitelbaum D, Sela M, and Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94:10821-10826.
5. Aharoni R, Teitelbaum D, Sela M, and Arnon R (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T-cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 91:135-146.
6. Arnon R and Sela M (2003) Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 16:412-421.
7. Baert F, Vermeire S, Noam M, Van Assche G, D'Haens G, and Rutgeerts P (2004) Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 5:304-314.
8. Boismenu R and Chen Y (2000) Insight from mouse models of colitis. J Leukoc Biol 67:267-278.
9. Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, and Boirivant M (2003) TGF-β1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 134:120-126.
10. Dieleman LA, Palmen HJ, Akol H, Bloemena E, Pena AS, Meuwissen SGM, and Van Rees EP (1998) Chronic experimental colitis induced by dextran sulphate sodium is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391.
11. Edelheit S and Meiri N (2004) Cyclin S: a new member of the cyclin family plays a role in long-term memory. Eur J Neurosci 19:365-375.
12. Farina C, Weber MS, Meinl E, Wekerle H, and Hohlfeld R (2005) Glatiramer acetate in multiple sclerosis: update on potential mechanism of action. Lancet Neurol 4:567-575.
13. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T, and Arnon R (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 91:4872-4876.
14. Gordon JN, Sabatino AD, and Macdonald TT (2005) The pathophysiological rational for biological therapies in inflammatory bowel disease. Curr Opin Gastroentrol 21:431-437.
15. Gur C, Karussis D, Golden E, Doron S, Ilan Y, and Safadi R (2006) Amelioration of experimental colitis by Copaxone is associated with class II-restricted CD4 immune blocking. Clin Immunol 118:307-316.
16. Kayhan B, Aharoni R, and Arnon R (2003) Glatiramer acetate (copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol Lett 8:185-192.
17. Kwon JH and Farrell RJ (2005) The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Oncol Hematol 56:169-178.
18. Li QQ, Burt DR, and Bever CT (2001) Glatiramer acetate inhibition of tumor necrosis factor-α-induced RANTES expression and release from U-251 MG human astrocytic cells. J Neurochem 77:1208-1217.
19. Mahler M and Leiter R (2002) Genetic and environmental context determines the course of colitis development in IL-10-deficient mice. Inflamm Bowel Dis 8:347-355.
20. Neuhaus O, Farina C, Yassouriclis A, Wiendl H, Then B, Dose T, Wekerle H, and Hohlfeld R (2000) Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper T helper 2 cells. Proc Natl Acad Sci USA 97:7452-7457.
21. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, and Strober W (1996) Experimental granulomatous colitis in mice is abrogated by induction of TGF-β mediated oral tolerance. J Exp Med 183:2605-2626.
22. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, et al. (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195:1129-1143.
23. Pizarro TT, Arsneau KO, Bamias G, and Cominelli F (2003) Mouse models for the study of Crohn's disease. Trends Mol Med 5:218-222.
24. Powrie F, Carlino J, Leach MW, Mauze S, and Coffman RL (1996) A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T-helper type 1-mediated colitis by CD45RB(low) CD4 T-cells. J Exp Med 183:2669-2674.
25. Rogler G and Andus T (1998) Cytokines in inflammatory bowel diseases. World J Surg 22:382-389.
26. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353:1912-1925.
27. Sandborn WJ and Targan SR (2002) Biologic therapy of IBD. Gastroenterology 122:1592-608.
28. Shanahan F (2001) IBD: Immunodiagnostics, immunotherapeutics, and ectotherapeutics. Gastroenterology 120:622-635.
29. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, and Neurath M (1997) Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 18:61-64.
30. Teitelbaum D, Arnon R, and Sela M (1999) Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci USA 96:3842-3847.